WAP
NBIX icon

Wealthcare Advisory Partners’s Neurocrine Biosciences NBIX Stock Holding History

Wealthcare Advisory Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$279K Sell
1,654
-11
-0.7% -$1.63K 0.01% 907
2026
Q1 		$219K Buy
1,665
+90
+6% +$11.9K ﹤0.01% 988
2025
Q4 		$223K Buy
+1,575
New +$228K ﹤0.01% 981

Other funds holding NBIX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PBBUPS
PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
AB
Amalgamated Bank New York $14.5B AUM 44.3% 1-Year Est. Return

Wealthcare Advisory Partners's NBIX Position: Q2 2026 in Review

Wealthcare Advisory Partners reduced its Neurocrine Biosciences (NBIX) stake by 0.66% in Q2 2026, selling an estimated $1.63K and leaving 1,654 shares worth $279K. The position accounts for 0.01% of the portfolio, ranked #907.

Wealthcare Advisory Partners first reported a position in NBIX in Q4 2025 and has held it in 3 quarters since. 166 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Wealthcare Advisory Partners held 1,654 shares of Neurocrine Biosciences worth $279K as of Q2 2026.
  • Wealthcare Advisory Partners sold 11 Neurocrine Biosciences shares in Q2 2026, an estimated $1.63K.
  • Neurocrine Biosciences made up 0.01% of Wealthcare Advisory Partners's portfolio in Q2 2026, its #907 holding.
  • Wealthcare Advisory Partners first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 166 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Wealthcare Advisory Partners's 13F filing for Q2 2026, filed 9 Jul 2026.